Nephrotoxicity of Immune Checkpoint Inhibitors: A Disproportionality Analysis from 2013 to 2020

This study aimed to systematically characterize nephrotoxicity after ICI initiation. Data were extracted from the US FDA Adverse Event Reporting System (FAERS) database. Disproportionality analysis, including information components (ICs) and reporting odds ratios (RORs), was performed to determine the potential renal toxicity of ICIs. A total of 7,204 reports of renal adverse events (AEs) were identified in the FAERS database. Renal AEs were most commonly reported for nivolumab (46.84%). Strong signals were detected in male patients combined with ICIs. In the clinical application of ICIs, attention should be paid to patients, especially male patients, with acute kidney injury, nephritis, autoimmune nephritis and other nephrotoxic AEs. The use of ICIs is likely to aggravate their condition.PMID:34433731 | DOI:10.1620/tjem.254.275

Source: The Tohoku Journal of Experimental Medicine - August 26, 2021 Category: Research Authors: Jiaming Qu Yanming Ding Kaiwen Jiang Junxia Hao Yuanzhi Li Aijun Zhang Zhaohang Li Guanpeng Qi Ze Xu Xin Liu Juman Ma Kaishun Bi Zuojing Li Source Type: research